 | • レポートコード：MRC23Q35787 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、69ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のアンチセンスオリゴヌクレオチド療法市場について調査・分析し、世界のアンチセンスオリゴヌクレオチド療法市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（GalNAc結合なし、GalNAc結合あり）、用途別セグメント分析（遺伝病、がん、循環器疾患、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Ionis Pharmaceuticals、Sarepta Therapeutics、Nippon Shinyakuなどが含まれています。世界のアンチセンスオリゴヌクレオチド療法市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、アンチセンスオリゴヌクレオチド療法市場規模を推定する際に考慮しました。本レポートは、アンチセンスオリゴヌクレオチド療法の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、アンチセンスオリゴヌクレオチド療法に関するビジネス上の意思決定に役立てることを目的としています。 ・アンチセンスオリゴヌクレオチド療法市場の概要 - アンチセンスオリゴヌクレオチド療法のタイプ別セグメント - 世界のアンチセンスオリゴヌクレオチド療法市場規模：タイプ別分析（GalNAc結合なし、GalNAc結合あり） - アンチセンスオリゴヌクレオチド療法の用途別セグメント - 世界のアンチセンスオリゴヌクレオチド療法市場規模：用途別分析（遺伝病、がん、循環器疾患、その他） - 世界のアンチセンスオリゴヌクレオチド療法市場規模予測（2018年-2029年） ・アンチセンスオリゴヌクレオチド療法市場の成長トレンド - アンチセンスオリゴヌクレオチド療法の地域別市場規模（2018年-2029年） - アンチセンスオリゴヌクレオチド療法市場ダイナミクス - アンチセンスオリゴヌクレオチド療法の業界動向 - アンチセンスオリゴヌクレオチド療法市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：GalNAc結合なし、GalNAc結合あり - 世界のアンチセンスオリゴヌクレオチド療法のタイプ別市場規模（2018年-2023年） - 世界のアンチセンスオリゴヌクレオチド療法のタイプ別市場規模（2024年-2029年） ・用途別セグメント：遺伝病、がん、循環器疾患、その他 - 世界のアンチセンスオリゴヌクレオチド療法の用途別市場規模（2018年-2023年） - 世界のアンチセンスオリゴヌクレオチド療法の用途別市場規模（2024年-2029年） ・アンチセンスオリゴヌクレオチド療法の地域別市場規模 - 北米のアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - アメリカのアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - ヨーロッパのアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - アジア太平洋のアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - 中国のアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - 日本のアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - 韓国のアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - インドのアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - オーストラリアのアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - 中南米のアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） - 中東・アフリカのアンチセンスオリゴヌクレオチド療法市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Ionis Pharmaceuticals、Sarepta Therapeutics、Nippon Shinyaku ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Antisense Oligonucleotide Therapies market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Antisense Oligonucleotide Therapies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Antisense Oligonucleotide Therapies in Genetic Disease is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Antisense Oligonucleotide Therapies include Ionis Pharmaceuticals, Sarepta Therapeutics and Nippon Shinyaku, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Antisense Oligonucleotide Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense Oligonucleotide Therapies.
The Antisense Oligonucleotide Therapies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Antisense Oligonucleotide Therapies market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antisense Oligonucleotide Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
Segment by Type
Without GalNAc-conjugated
With GalNAc-conjugated
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antisense Oligonucleotide Therapies companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotide Therapies Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Without GalNAc-conjugated
1.2.3 With GalNAc-conjugated
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotide Therapies Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Genetic Disease
1.3.3 Cancer
1.3.4 Cardiovascular Diseases
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antisense Oligonucleotide Therapies Market Perspective (2018-2029)
2.2 Antisense Oligonucleotide Therapies Growth Trends by Region
2.2.1 Global Antisense Oligonucleotide Therapies Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Antisense Oligonucleotide Therapies Historic Market Size by Region (2018-2023)
2.2.3 Antisense Oligonucleotide Therapies Forecasted Market Size by Region (2024-2029)
2.3 Antisense Oligonucleotide Therapies Market Dynamics
2.3.1 Antisense Oligonucleotide Therapies Industry Trends
2.3.2 Antisense Oligonucleotide Therapies Market Drivers
2.3.3 Antisense Oligonucleotide Therapies Market Challenges
2.3.4 Antisense Oligonucleotide Therapies Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense Oligonucleotide Therapies Players by Revenue
3.1.1 Global Top Antisense Oligonucleotide Therapies Players by Revenue (2018-2023)
3.1.2 Global Antisense Oligonucleotide Therapies Revenue Market Share by Players (2018-2023)
3.2 Global Antisense Oligonucleotide Therapies Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antisense Oligonucleotide Therapies Revenue
3.4 Global Antisense Oligonucleotide Therapies Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotide Therapies Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide Therapies Revenue in 2022
3.5 Antisense Oligonucleotide Therapies Key Players Head office and Area Served
3.6 Key Players Antisense Oligonucleotide Therapies Product Solution and Service
3.7 Date of Enter into Antisense Oligonucleotide Therapies Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense Oligonucleotide Therapies Breakdown Data by Type
4.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Type (2018-2023)
4.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Type (2024-2029)
5 Antisense Oligonucleotide Therapies Breakdown Data by Application
5.1 Global Antisense Oligonucleotide Therapies Historic Market Size by Application (2018-2023)
5.2 Global Antisense Oligonucleotide Therapies Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Antisense Oligonucleotide Therapies Market Size (2018-2029)
6.2 North America Antisense Oligonucleotide Therapies Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
6.4 North America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antisense Oligonucleotide Therapies Market Size (2018-2029)
7.2 Europe Antisense Oligonucleotide Therapies Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
7.4 Europe Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense Oligonucleotide Therapies Market Size (2018-2029)
8.2 Asia-Pacific Antisense Oligonucleotide Therapies Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Antisense Oligonucleotide Therapies Market Size by Region (2018-2023)
8.4 Asia-Pacific Antisense Oligonucleotide Therapies Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antisense Oligonucleotide Therapies Market Size (2018-2029)
9.2 Latin America Antisense Oligonucleotide Therapies Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
9.4 Latin America Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense Oligonucleotide Therapies Market Size (2018-2029)
10.2 Middle East & Africa Antisense Oligonucleotide Therapies Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2018-2023)
10.4 Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ionis Pharmaceuticals
11.1.1 Ionis Pharmaceuticals Company Detail
11.1.2 Ionis Pharmaceuticals Business Overview
11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Introduction
11.1.4 Ionis Pharmaceuticals Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.1.5 Ionis Pharmaceuticals Recent Development
11.2 Sarepta Therapeutics
11.2.1 Sarepta Therapeutics Company Detail
11.2.2 Sarepta Therapeutics Business Overview
11.2.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Introduction
11.2.4 Sarepta Therapeutics Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.2.5 Sarepta Therapeutics Recent Development
11.3 Nippon Shinyaku
11.3.1 Nippon Shinyaku Company Detail
11.3.2 Nippon Shinyaku Business Overview
11.3.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Introduction
11.3.4 Nippon Shinyaku Revenue in Antisense Oligonucleotide Therapies Business (2018-2023)
11.3.5 Nippon Shinyaku Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details